"You will discover constrained and very limited permissions for specific pharmaceutical companies to implement that substance for investigate needs and for extremely precise narrowly prescribed health-related purposes," he discussed.Ought to Adastra stray from these rigid problems, Overall health Canada stated it “will not hesitate to get action,